肌层浸润性膀胱癌新辅助试验中根治性膀胱切除病理完全缓解的替代终点评估
两步分析显示pCR与3年OS关联弱(R2=0.30),治疗效应对pCR与OS的关联差(R2=0.06),排除高偏倚风险试验后改善有限。结论不支持pCR作为独立替代终点用于试验设计或把握度计算。
要点
- pCR与3年OS的试验级关联弱,R2仅0.30,排除高偏倚风险试验后为0.50。
- 治疗效应对pCR与OS的关联差,8项RCT中R2=0.06,排除高偏倚后仅0.42。
- pCR虽具预后信息,但未达OS的正式试验级替代标准,不宜单独作为注册试验终点。
核心结论
- pCR虽具预后价值,但未满足OS的正式试验级替代标准,不支持作为独立替代终点用于肌层浸润性膀胱癌新辅助注册试验的设计或把握度计算。
研究设计与样本
- 系统评价与荟萃替代分析(PROSPERO CRD420251050357),纳入2003-2026年前瞻性非随机试验和随机对照试验,评估非转移性肌层浸润性膀胱癌新辅助治疗后根治性膀胱切除。
主要发现
- 第一步分析中,所有试验的pCR与3年OS关联弱(R2=0.30,95%CI 0-0.70),排除高偏倚风险试验后改善至中等(R2=0.50,95%CI 0.20-0.80)。
- 第二步分析中,8项RCT(n=2622)的治疗效应对pCR与OS的关联差(R2=0.06,95%CI 0-0.84),排除高偏倚风险试验后改善至弱(R2=0.42)。
- 仅限化疗或含免疫治疗的RCT敏感性分析显示替代性能同样有限。
关键数值与推荐
- 第一步:试验组pCR率与标志性3年或4年OS的关联,采用逆方差加权线性回归。
- 第二步:pCR治疗效应log(1/OR)与OS的log(HR)的关联,以决定系数R2量化替代强度。
临床怎么用
- 临床解读新辅助试验时,pCR可作预后参考但不宣单独作为OS替代终点。
- 设计或计算肌层浸润性膀胱癌注册试验把握度时,不应以pCR替代OS。
局限性
- 部分试验存在高偏倚风险,排除后关联改善但仍有限。
- 敏感性分析限于化疗或含免疫治疗RCT,替代性能同样有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Overall survival (OS) remains the gold standard end point in neoadjuvant trials for muscle-invasive bladder cancer (MIBC), yet its assessment requires prolonged follow-up. Whether pathological complete response (pCR) at radical cystectomy (RC) can serve as a valid trial-level surrogate remains unclear. To test this hypothesis, we conducted a systematic review and meta-analytic surrogacy analysis (PROSPERO CRD420251050357) of prospective nonrandomized trials and randomized controlled trials (RCTs) evaluating neoadjuvant therapies followed by RC in nonmetastatic MIBC (2003-2026). Eligible trials reported pCR and provided 3- and/or 4-yr OS via Kaplan-Meier curves, enabling survival reconstruction. Analyses followed an intention-to-treat approach. Surrogacy was evaluated using a two-step trial-level framework: (1) association between trial-arm pCR rates and landmark 3- or 4-yr OS using inverse-variance-weighted linear regression and (2) association between treatment effects log(1/Odds ratio (OR)) on pCR and log(hazard ratio [HR]) for OS, with the coefficient of determination (R2) quantifying surrogacy strength. Twelve trials (n = 3119 patients) met the eligibility criteria. In first-step analyses, the association between pCR and 3-yr OS across all trials was weak (R2 = 0.30, 95% confidence interval [CI] = 0-0.70) and improved to moderate after excluding trials at high risk of bias (R2 = 0.50, 95% CI = 0.20-0.80). In second-step analyses across eight RCTs (n = 2622), the association between treatment effects on pCR and OS was poor (R2 = 0.06, 95% CI = 0-0.84) and improved to weak after excluding high-risk trials (R2 = 0.42). Sensitivity analyses restricted to chemotherapy-only or immunotherapy-containing RCTs yielded similarly limited surrogacy performance. To conclude, although pCR remains prognostically informative, it did not meet formal trial-level surrogacy criteria for OS. These findings do not support the use of pCR as a stand-alone surrogate end point for designing or powering registrational neoadjuvant-based MIBC trials.
引用
- Scilipoti P, Ślusarczyk A, Thibault C, et al. Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials. Eur Urol Oncol. 2026. PMID: 42342498. doi:10.1016/j.euo.2026.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。